Among 56 intermediated risk group (i.e. de novo CN-AML with other than mutated NPM1 without FLT3-ITD) patients, 46 (81.2%) had received intensive chemotherapy, and 6 (10.7%) received low intensity chemotherapy. Here, FLT3 is linked to acute myeloid leukemia.